Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patiromer Add-On to Spironolactone in T2DM and CKD (MAGMAAddOn)
NCT03597035Phase 4Terminated
- Sponsor
- University Hospitals Cleveland Medical Center
- Start
- Jul 2018
- Primary completion
- Jul 2020
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of patiromer, spironolactone in type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), atherosclerosis, hyperkalemia, sponsored by University Hospitals Cleveland Medical Center. Started Jul 2018; status: terminated.
02
Drugs
patiromerspironolactone
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)atherosclerosishyperkalemia
Beyond the preview
Go deeper on NCT03597035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03597035.